Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: BFRIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.08% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7102407 |
Shares Outstanding - | Shares Floating 7102407 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The warrants represent the right to purchase shares of Biofrontera Inc. stock. Details on the warrant history (issuance, expirations, terms) require access to specific financial documents which are not readily available and are not included.
Core Business Areas
- Pharmaceuticals: Focuses on developing and commercializing pharmaceutical products for dermatology, particularly treatments for actinic keratoses.
Leadership and Structure
Details on leadership team (CEO, CFO) and organizational structure are not readily available and are not included.
Top Products and Market Share
Key Offerings
- Ameluz: A topical prescription drug approved for the treatment of actinic keratoses on the face and scalp. Market share data specific to Ameluz compared to its competitors is not readily available. Competitors include topical fluorouracil, imiquimod, and photodynamic therapy with other photosensitizers.
Market Dynamics
Industry Overview
The dermatology market is driven by an aging population, increased awareness of skin conditions, and advancements in treatment options.
Positioning
Biofrontera focuses on a specific niche within dermatology, addressing actinic keratoses. Its competitive advantage is based on the efficacy and patient convenience of its products.
Total Addressable Market (TAM)
The TAM for actinic keratosis treatment is estimated to be several billion dollars globally. Biofrontera is positioned to capture a portion of this market with its Ameluz product.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Ameluz)
- Specialized focus on dermatology
- Established sales and marketing infrastructure
Weaknesses
- Dependence on a single key product
- Limited financial resources compared to larger pharmaceutical companies
- Vulnerability to generic competition
Opportunities
- Expanding into new geographic markets
- Developing new formulations or indications for existing products
- Acquiring complementary dermatological assets
Threats
- Competition from existing and new therapies
- Changes in healthcare regulations and reimbursement policies
- Product liability claims
Competitors and Market Share
Key Competitors
- LEO Pharma
- Galderma
- Sun Pharmaceutical Industries
- Perrigo Company plc
- Almirall, S.A.
Competitive Landscape
Biofrontera is a smaller player in the dermatology market compared to larger pharmaceutical companies. Its competitive advantage lies in its specialized focus and innovative products. The market is competitive, requiring robust sales and marketing efforts.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in Biofrontera Inc.'s revenue and sales figures. This data is not included in this output.
Future Projections: Future projections depend on factors such as market penetration, new product development, and regulatory approvals. These projections require access to analyst reports.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts and pursuing regulatory approvals in new markets. This data is not included.
Summary
Biofrontera Inc. is a biopharmaceutical company with a focus on dermatology. The warrants' value is dependent on the performance of the underlying stock (BFRI). The company faces competition from larger players and relies on a key product. Expansion into new markets and product development are crucial for future growth, while competitive pressures and regulatory changes pose potential threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (unavailable)
Disclaimers:
This analysis is based on limited publicly available information. Market share data and competitor analysis are estimates. The warrants' value is subject to market conditions and Biofrontera Inc.'s performance. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.